By targeting a new mechanism further downstream in the sepsis pathway than previous approaches, Adrenomed thinks it can escape the graveyard that has sunk drug development in the indication. Its approach hinges on preventing the vascular damage that triggers progression to shock, and using a companion diagnostic to identify patients most likely to get to that point.
Adrenomed AG’s first-in-class antibody, which binds the biologically active form of the peptide hormone adrenomedullin (ADM), is designed to prevent progression from sepsis to septic shock.
Most of the therapies in development target the sources of sepsis: the infecting bacteria, the toxins they produce, and the widespread immune response that results.
The only therapies approved for the indication are antiseptic agents, and standard of care involves supportive treatments such as fluids and vasopressors. Ten of the 13 compounds in the clinic are designed to combat the dangerous levels of inflammation, two target the endotoxin released from bacteria, and one is a vasopressor. None targets vascular integrity.
For most diseases, getting to the source of the problem is the goal, but